Korro to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Korro Bio (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, has announced its participation in two upcoming investor conferences. At the 2024 Cantor Global Healthcare Conference on September 17, COO Todd Chappell will engage in a fireside chat, while CFO Vineet Agarwal will attend investor meetings. At Chardan's 8th Annual Genetic Medicines Conference on September 30, CEO and President Ram Aiyar will participate in a fireside chat, with Agarwal also in attendance.
Both fireside chats will be webcast live and accessible through Korro's website, with replays available for 30 days post-event. These conferences provide Korro an opportunity to showcase its innovative approach to genetic medicine and engage with investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, KRRO gained 0.94%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
2024 Cantor Global Healthcare Conference
Todd Chappell, Chief Operating Officer, will participate in a fireside chat on Tuesday, September 17, 2024, at 10:55 a.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the conference.
Chardan’s 8th Annual Genetic Medicines Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Monday, September 30, 2024, at 2:30 p.m. ET. Mr. Agarwal will also be participating at the conference.
The live webcasts of the Cantor and Chardan fireside chats can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentations, a replay of the event will be available for 30 days.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
FAQ
What investor conferences will Korro Bio (KRRO) attend in September 2024?
Who from Korro Bio (KRRO) will speak at the 2024 Cantor Global Healthcare Conference?
When is Ram Aiyar from Korro Bio (KRRO) scheduled to speak at Chardan's conference?
How can investors access Korro Bio's (KRRO) presentations at these conferences?
What type of genetic medicines is Korro Bio (KRRO) developing?
